|
1
|
Fangusaro J, Jones DT, Packer RJ, Gutmann
DH, Milde T, Witt O, Mueller S, Fisher MJ, Hansford JR, Tabori U,
et al: Pediatric low-grade glioma: State-of-the-art and ongoing
challenges. Neuro Oncol. 26:25–37. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Crotty EE, Sato AA and Abdelbaki MS:
Integrating MAPK pathway inhibition into standard-of-care therapy
for pediatric low-grade glioma. Front Oncol.
15(1520316)2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cacciotti C, Tabori U, Hawkins C and
Bennett J: Targeting the RAS/MAPK pathway in children with glioma.
J Neurooncol. 171:265–277. 2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Renzi S, Bennett J, Thacker N and
Cacciotti C: Precision medicine for pediatric glioma and
NF1-Associated tumors: The role of small molecule inhibitors. Curr
Oncol. 32(280)2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Das J, Adhikari N, Pal A, Chongder T, Dule
S, Sarma A, Dutta S, Gupta P and Shome A: Exploring the effects of
ROS on PI3K/AKT/mTOR signalling in pediatric low-grade glioma and
therapeutic strategies. Mol Biol Rep. 52(916)2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Peters KB: New and emerging therapies for
patients with Low-grade glioma. CNS Drugs. 4:1–18. 2026.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Malagrinò F, Puglisi E, Pagano L,
Travaglini-Allocatelli C and Toto A: GRB2: A dynamic adaptor
protein orchestrating cellular signaling in health and disease.
Biochem Biophys Rep. 39(101803)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sullivan RJ, Tsai KK, Pavlick AC,
Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G and
Olszanski AJ: Phase 1b study of tovorafenib, plozalizumab or
vedolizumab plus Standard-of-Care immune checkpoint inhibitors in
patients with advanced melanoma. J Cancer. 16:3797–3809.
2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Singh S, Bradford D, Chatterjee S, Li X,
Aungst SL, Skinner AM, Miller CP, Kim-McOlash S, Fourie Zirkelbach
J, Xiong Y, et al: FDA approval summary: Tovorafenib for relapsed
or refractory BRAF-Altered pediatric Low-grade glioma. Clin Cancer
Res. 31:1383–1389. 2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kilburn LB, Khuong-Quang DA, Hansford JR,
Landi D, van der Lugt J, Leary SES, Driever PH, Bailey S, Perreault
S, McCowage G, et al: The type II RAF inhibitor tovorafenib in
relapsed/refractory pediatric low-grade glioma: The phase 2
FIREFLY-1 trial. Nat Med. 30:207–217. 2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu HN, Zhu Y, Chi Y, Sun FF, Shan LS,
Wang YT and Dai B: Synthetic approaches and application of
representative clinically approved fluorine-enriched anti-cancer
medications. Eur J Med Chem. 276(116722)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Benedetto Tiz D, Rosati O and Sancineto L:
‘Sulfur- and phosphorus-containing FDA approved drugs in the last
five years (2020-2024): A journey among small molecules’,
Phosphorus, Sulfur, and Silicon and the Related Elements, pp1-39,
2025 doi: 10.1080/10426507.2025.2496521.
|
|
13
|
Zhang Y, Preigh M, Wang J, Venetsanakos E,
Wang Y, Barry E and Corson D: Taste profile and relative
bioavailability of tovorafenib powder for oral suspension and food
effect of the tovorafenib tablet in healthy participants. Clin
Pharmacol Drug Dev. 14:669–679. 2025.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rastogi S, Perino S, Lal-Nag M, Wang Y,
Blackman SC and Venetsanakos E: Preclinical activity of the type II
RAF inhibitor tovorafenib in tumor models harboring either a BRAF
fusion or an NF1 Loss-of-Function mutation. Cancer Res Commun.
5:668–679. 2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Nysom K, Kilburn LB, Leary SES, Landi DB,
de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever
P, Franson AT, et al: Radiographic and visual response to the type
II RAF inhibitor tovorafenib in children with relapsed/refractory
optic pathway glioma in the FIREFLY-1 trial. Neuro Oncol.
27:1341–1355. 2025.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang T, Xu B, Tang F, He Z and Zhou J:
Type II RAF inhibitor tovorafenib for the treatment of pediatric
low-grade glioma. Expert Rev Clin Pharmacol. 17:999–1008.
2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dhillon S: Tovorafenib: First approval.
Drugs. 84:985–993. 2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Khoury JE, Wehbe S, Attieh F, Boutros M,
Kesrouani C and Kourie HR: A critical review of RAF inhibitors in
BRAF-mutated glioma treatment. Pharmacogenomics. 25:343–355.
2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tkacik E, Li K, Gonzalez-Del Pino G, Ha
BH, Vinals J, Park E, Beyett TS and Eck MJ: Structure and RAF
family kinase isoform selectivity of type II RAF inhibitors
tovorafenib and naporafenib. J Biol Chem.
299(104634)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ren C, Zhang M, Liu J, Zhang L, Guan X, Pu
S and Li J: Dual inhibition of BRAF for cancer treatment: Advances
and therapeutic potential. Future Med Chem. 17:1–16.
2025.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Araujo DV, Souza BL, Seibel MF, Fares AF
and Liutti VT: Dabrafenib and trametinib vs anti-PD(L)1 for the
adjuvant treatment of locally advanced BRAF-mutant melanoma: A
systematic review and meta-analysis. Oncologist.
30(oyaf247)2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mechahougui H, Gutmans J, Gouasmi R,
Smekens L and Friedlaender A: BRAF Targeting across solid tumors:
Molecular aspects and clinical applications. Int J Mol Sci.
26(3757)2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bockorny B, Rusan M, Chen W, Liao RG, Li
Y, Piccioni F, Wang J, Tan L, Thorner AR, Li T, et al: RAS-MAPK
reactivation facilitates acquired resistance in FGFR1-Amplified
lung cancer and underlies a rationale for upfront FGFR-MEK
blockade. Mol Cancer Ther. 17:1526–1539. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fan QW and Weiss WA: Targeting the
RTK-PI3K-mTOR axis in malignant glioma: Overcoming resistance. Curr
Top Microbiol Immunol. 347:279–296. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ziegler DS, Lehmann R and Eisenstat DD: A
paradigm shift in how we treat pediatric low-grade glioma-Targeting
the molecular drivers. Neuro Oncol. 26:593–595. 2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rittler D, Molnár E, Baranyi M, Garay T,
Hegedűs L, Aigner C, Tóvári J, Tímár J and Hegedűs B: Horizontal
Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor
cells with or without concomitant PI3K pathway mutations. Int J Mol
Sci. 21(7649)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Offer K, McGuire MT, Song K, Goldfischer
MJ, Davare MA, Corless CL, Beadling C, Neff T, Cox MC, Govinda Raju
S and Blackman SC: Activity of type II RAF inhibitor tovorafenib in
a pediatric patient with a recurrent spindle cell sarcoma harboring
a novel SNX8-BRAF gene fusion. JCO Precis Oncol.
7(e2300065)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rasco DW, Medina T, Corrie P, Pavlick AC,
Middleton MR, Lorigan P, Hebert C, Plummer R, Larkin J, Agarwala
SS, et al: Phase 1 study of the pan-RAF inhibitor tovorafenib in
patients with advanced solid tumors followed by dose expansion in
patients with metastatic melanoma. Cancer Chemother Pharmacol.
92:15–28. 2023.PubMed/NCBI View Article : Google Scholar
|
